This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hayden, M. K.
Right arrow Articles by Weinstein, R. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hayden, M. K.
Right arrow Articles by Weinstein, R. A.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, October 2005, p. 5285-5287, Vol. 43, No. 10
0095-1137/05/$08.00+0     doi:10.1128/JCM.43.10.5285-5287.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.

Development of Daptomycin Resistance In Vivo in Methicillin-Resistant Staphylococcus aureus

M. K. Hayden,1* K. Rezai,1,2 R. A. Hayes,1 K. Lolans,2 J. P. Quinn,1,2 and R. A. Weinstein1,2

Rush University Medical Center, Chicago, Illinois,1 Stroger (Cook County) Hospital, Chicago, Illinois2

Received 17 May 2005/ Returned for modification 14 June 2005/ Accepted 11 July 2005

Daptomycin is a new lipopeptide antibiotic that is rapidly bactericidal against Staphylococcus aureus. We report daptomycin resistance and treatment failure in 2 patients with osteomyelitis due to methicillin-resistant S. aureus. Disk diffusion susceptibility testing failed to detect resistance. Daptomycin at high concentration retained bactericidal activity against resistant isolates.

* Corresponding author. Mailing address: Rush University Medical Center, 1653 W. Congress Parkway, Chicago, IL 60612. Phone: (312) 942-5445. Fax: (312) 942-6787. E-mail: mhayden{at}rush.edu.

Journal of Clinical Microbiology, October 2005, p. 5285-5287, Vol. 43, No. 10
0095-1137/05/$08.00+0     doi:10.1128/JCM.43.10.5285-5287.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Vidaillac, C., Leonard, S. N., Rybak, M. J. (2009). In Vitro Activity of Ceftaroline against Methicillin-Resistant Staphylococcus aureus and Heterogeneous Vancomycin-Intermediate S. aureus in a Hollow Fiber Model. Antimicrob. Agents Chemother. 53: 4712-4717 [Abstract] [Full Text]  
  • Miro, J. M., Garcia-de-la-Maria, C., Armero, Y., Soy, D., Moreno, A., del Rio, A., Almela, M., Sarasa, M., Mestres, C. A., Gatell, J. M., Jimenez de Anta, M. T., Marco, F., and the Hospital Clinic Experimental Endocarditis, (2009). Addition of Gentamicin or Rifampin Does Not Enhance the Effectiveness of Daptomycin in Treatment of Experimental Endocarditis Due to Methicillin-Resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 53: 4172-4177 [Abstract] [Full Text]  
  • Yang, S.-J., Xiong, Y. Q., Dunman, P. M., Schrenzel, J., Francois, P., Peschel, A., Bayer, A. S. (2009). Regulation of mprF in Daptomycin-Nonsusceptible Staphylococcus aureus Strains. Antimicrob. Agents Chemother. 53: 2636-2637 [Abstract] [Full Text]  
  • Kirby, A., Mohandas, K., Broughton, C., Neal, T. J., Smith, G. W., Pai, P., Nistal de Paz, C. (2009). In vivo development of heterogeneous glycopeptide-intermediate Staphylococcus aureus (hGISA), GISA and daptomycin resistance in a patient with meticillin-resistant S. aureus endocarditis. J Med Microbiol 58: 376-380 [Abstract] [Full Text]  
  • Camargo, I. L. B. d. C., Neoh, H.-M., Cui, L., Hiramatsu, K. (2008). Serial Daptomycin Selection Generates Daptomycin-Nonsusceptible Staphylococcus aureus Strains with a Heterogeneous Vancomycin-Intermediate Phenotype. Antimicrob. Agents Chemother. 52: 4289-4299 [Abstract] [Full Text]  
  • Hawkey, P. M. (2008). Pre-clinical experience with daptomycin. J Antimicrob Chemother 62: iii7-iii14 [Abstract] [Full Text]  
  • Levine, D. P. (2008). Clinical experience with daptomycin: bacteraemia and endocarditis. J Antimicrob Chemother 62: iii35-iii39 [Abstract] [Full Text]  
  • Warren, R. E. (2008). Daptomycin in endocarditis and bacteraemia: a British perspective. J Antimicrob Chemother 62: iii25-iii33 [Abstract] [Full Text]  
  • Wargo, K. A., Eiland, E. H. III, Eiland, L. S. (2008). Management and Treatment Considerations for Infections Caused by Methicillin-Resistant Staphylococcus aureus. Journal of Pharmacy Practice 21: 324-336 [Abstract]  
  • Bailey, J., Summers, K. M. (2008). Dalbavancin: A new lipoglycopeptide antibiotic. Am J Health Syst Pharm 65: 599-610 [Abstract] [Full Text]  
  • Rose, W. E., Leonard, S. N., Sakoulas, G., Kaatz, G. W., Zervos, M. J., Sheth, A., Carpenter, C. F., Rybak, M. J. (2008). Daptomycin Activity against Staphylococcus aureus following Vancomycin Exposure in an In Vitro Pharmacodynamic Model with Simulated Endocardial Vegetations. Antimicrob. Agents Chemother. 52: 831-836 [Abstract] [Full Text]  
  • Montero, C. I., Stock, F., Murray, P. R. (2008). Mechanisms of Resistance to Daptomycin in Enterococcus faecium. Antimicrob. Agents Chemother. 52: 1167-1170 [Abstract] [Full Text]  
  • Huang, Y.-T., Hsiao, C.-H., Liao, C.-H., Lee, C.-W., Hsueh, P.-R. (2008). Bacteremia and Infective Endocarditis Caused by a Non-Daptomycin-Susceptible, Vancomycin-Intermediate, and Methicillin-Resistant Staphylococcus aureus Strain in Taiwan. J. Clin. Microbiol. 46: 1132-1136 [Abstract] [Full Text]  
  • Jones, T., Yeaman, M. R., Sakoulas, G., Yang, S.-J., Proctor, R. A., Sahl, H.-G., Schrenzel, J., Xiong, Y. Q., Bayer, A. S. (2008). Failures in Clinical Treatment of Staphylococcus aureus Infection with Daptomycin Are Associated with Alterations in Surface Charge, Membrane Phospholipid Asymmetry, and Drug Binding. Antimicrob. Agents Chemother. 52: 269-278 [Abstract] [Full Text]  
  • Julian, K., Kosowska-Shick, K., Whitener, C., Roos, M., Labischinski, H., Rubio, A., Parent, L., Ednie, L., Koeth, L., Bogdanovich, T., Appelbaum, P. C. (2007). Characterization of a Daptomycin-Nonsusceptible Vancomycin-Intermediate Staphylococcus aureus Strain in a Patient with Endocarditis. Antimicrob. Agents Chemother. 51: 3445-3448 [Abstract] [Full Text]  
  • Rose, W. E., Rybak, M. J., Kaatz, G. W. (2007). Evaluation of daptomycin treatment of Staphylococcus aureus bacterial endocarditis: an in vitro and in vivo simulation using historical and current dosing strategies. J Antimicrob Chemother 60: 334-340 [Abstract] [Full Text]  
  • Goldstein, F. (2007). The potential clinical impact of low-level antibiotic resistance in Staphylococcus aureus. J Antimicrob Chemother 59: 1-4 [Abstract] [Full Text]  
  • Aiello, A. E., King, N. B., Foxman, B. (2006). Ethical Conflicts in Public Health Research and Practice: Antimicrobial Resistance and the Ethics of Drug Development. AJPH 96: 1910-1914 [Abstract] [Full Text]  
  • Jevitt, L. A., Thorne, G. M., Traczewski, M. M., Jones, R. N., McGowan, J. E. Jr., Tenover, F. C., Brown, S. D. (2006). Multicenter Evaluation of the Etest and Disk Diffusion Methods for Differentiating Daptomycin-Susceptible from Non-Daptomycin-Susceptible Staphylococcus aureus Isolates.. J. Clin. Microbiol. 44: 3098-3104 [Abstract] [Full Text]  
  • Fowler, V. G. Jr., Boucher, H. W., Corey, G. R., Abrutyn, E., Karchmer, A. W., Rupp, M. E., Levine, D. P., Chambers, H. F., Tally, F. P., Vigliani, G. A., Cabell, C. H., Link, A. S., DeMeyer, I., Filler, S. G., Zervos, M., Cook, P., Parsonnet, J., Bernstein, J. M., Price, C. S., Forrest, G. N., Fatkenheuer, G., Gareca, M., Rehm, S. J., Brodt, H. R., Tice, A., Cosgrove, S. E., the S. aureus Endocarditis and Bacteremia Study Gr, (2006). Daptomycin versus Standard Therapy for Bacteremia and Endocarditis Caused by Staphylococcus aureus.. NEJM 355: 653-665 [Abstract] [Full Text]  
  • Denis, O., Deplano, A., Nonhoff, C., Hallin, M., De Ryck, R., Vanhoof, R., De Mendonca, R., Struelens, M. J. (2006). In Vitro Activities of Ceftobiprole, Tigecycline, Daptomycin, and 19 Other Antimicrobials against Methicillin-Resistant Staphylococcus aureus Strains from a National Survey of Belgian Hospitals.. Antimicrob. Agents Chemother. 50: 2680-2685 [Abstract] [Full Text]  
  • Tyrrell, K. L., Citron, D. M., Warren, Y. A., Fernandez, H. T., Merriam, C. V., Goldstein, E. J. C. (2006). In Vitro Activities of Daptomycin, Vancomycin, and Penicillin against Clostridium difficile, C. perfringens, Finegoldia magna, and Propionibacterium acnes.. Antimicrob. Agents Chemother. 50: 2728-2731 [Abstract] [Full Text]  
  • Friedman, L., Alder, J. D., Silverman, J. A. (2006). Genetic Changes That Correlate with Reduced Susceptibility to Daptomycin in Staphylococcus aureus.. Antimicrob. Agents Chemother. 50: 2137-2145 [Abstract] [Full Text]  
  • Jorgensen, J. H., Crawford, S. A. (2006). Assessment of Two Commercial Susceptibility Test Methods for Determination of Daptomycin MICs.. J. Clin. Microbiol. 44: 2126-2129 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»